Compare Enact Holdings Inc (ACT) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Enact Holdings Inc trades at $49.93 (market cap $6.75B), while Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.4× Enact Holdings Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ACT | ALNY | |
|---|---|---|
Market Cap | $6.75B | $29.60B |
Sector | Technology | Health |
52-Week High | $49.12 | $491.22 |
52-Week Low | $34.93 | $205.48 |
Enterprise Value | $7.05B | $27.56B |
Dividend Yield | 1.95% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
